Like Iconix Biosciences, Inc.

closed 8/30/2007 via Company Press Release

Entelos Inc., acquired Iconix Biosciences, Inc.

synopsis: Entelos, Inc., a leading life sciences company that leverages its proprietary in silico disease models, known as PhysioLab® platforms, to develop drugs and support pharmaceutical R&D, is pleased to announce that it has entered into an agreement to acquire Iconix Biosciences, Inc., a privately held predictive toxicology company
buyer: Entelos Inc.
Entelos partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease and dramatically reduce the time and cost needed to develop them. Using our patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. "
target: Iconix Biosciences, Inc.
Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix®)
price ($mm)
$7.73
rev ($mm)
$5
EBITDA ($mm)
EV / rev
6.7x
EV / EBITDA
closed 5/21/2019 via BusinessWire

Xcenda, acquired Dymaxium, Inc.

synopsis: Xcenda, a part of AmerisourceBergen, announced the acquisition of Dymaxium, a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
buyer parent: AmerisourceBergen Corporation
buyer: Xcenda
Xcenda, part of AmerisourceBergen, is a strategic consultancy with 20+ years of experience applying real-world expertise in health economics and outcomes research, reimbursement, stakeholder insights, and market access consulting and communications. "
target: Dymaxium, Inc.
Dymaxium is a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2016 via BNC Analysis

M3, Inc., will acquire Vidal Group

synopsis: Electra Partners’ portfolio company AXIO Group has received a binding offer from M3 Inc. to purchase Vidal Group, a European provider of reference drug information. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients with on-line access to up-to-date drug databases and related treatment-based information.
buyer: M3, Inc. (TSE:2413:$1,110.45)
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet. "
target parent: Electra Partners LLP
target: Vidal Group
Vidal Group is a leading European healthcare informatics and information systems company. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients across Europe with on-line access to up-to-date drug databases and related treatment-based information.
price ($mm)
$133
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/30/2016 via BNC Analysis

Affinity Equity Partners, will acquire MedicalDirector

synopsis: Leading Asian private equity firm Affinity Equity Partners agreed to acquire Sydney-based MedicalDirector (formerly Health Communication Network) from Australia’s Primary Health Care Ltd. MedicalDirector is a leading provider of clinical and enterprise software solutions to general practitioners, medical specialists and allied health professionals.
buyer: Affinity Equity Partners
Affinity Equity Partners is an independently-owned buyout fund manager comprising primarily the former investment professionals of UBS Capital Asia Pacific. They are pioneers in buyout investments in the Asia-Pacific region, with an established and widely recognised franchise. "
target parent: Primary Health Care Limited
target: MedicalDirector
MedicalDirector has been supporting healthcare professionals and improving health outcomes for more than 20 years. They provide software for practice management, optimizing patient outcomes, and access to Australia's most comprehensive and up-to-date pharmaceutical database.
price ($mm)
$119
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/26/2015 via Company Press Release

Inovalon, Inc., will acquire Avalere Health LLC

synopsis: Inovalon, a leading technology company providing cloud-based analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
buyer: Inovalon, Inc. (INOV:$449.36)
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. "
target: Avalere Health LLC
Avalere Health, Inc. is a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
price ($mm)
$140
rev ($mm)
$47
EBITDA ($mm)
EV / rev
3.0x
EV / EBITDA
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
closed 7/22/2010 via Company Press Release

CT Corsearch, acquired Edital

synopsis: CT Corsearch, the premier provider of clearance and protection solutions for trademark and brand professionals, announced it’s acquired Edital, the Questel trademark branch. This acquisition will create best-in-class solutions for managing a brand lifecycle globally—from creation to watching to protecting, maintaining and renewing a brand.
buyer parent: Wolters Kluwer NV
buyer: CT Corsearch
CT Corsearch provides high-quality, intuitive tools and expertise that trademark professionals need to effectively manage the trademark screening, search review and watching processes. "
target parent: Questel
target: Edital
Edital was established in Brussels in 1982 and acquired by Questel, a world leader in Intellectual Property in 2005. Its sole purpose has been to create global solutions for the Intellectual Property professional.
price ($mm)
rev ($mm)
$8
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/21/2010 via Company Press Release

MedMeme LLC, acquired Medical Intelligence Solutions

synopsis: MedMeme, LLC, a leading provider of key opinion leader data and competitive intelligence to the healthcare, pharmaceutical, and biotechnical industries, announced the recent acquisition of Medical Intelligence Solutions (MIS), the world's foremost provider of information on medical meeting content.
buyer: MedMeme LLC
MedMeme™ LLC is a medical opinion leader database company serving the pharmaceutical and biotech community worldwide. MedMeme focuses on providing in-depth, comprehensive, accurate, and actionable competitive intelligence on all aspects of medical research and the experts who work in the field. "
target: Medical Intelligence Solutions
Medical Intelligence Solutions (MIS) provides key clinical data presented at domestic and international medical meetings relevant to the development and marketing of pharmaceuticals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/3/2008 via BtoBonline.com

Gemini Healthcare, LLC, acquired MCM Group

synopsis: Marketing agency Gemini Healthcare has acquired MCM Group, a data analytics and benchmarking applications provider. Financial terms of the deal were not disclosed. MCM Group delivers its benchmarks programs through a proprietary platform called Total Resource Utilization that will now be available to Gemini's clients.
buyer: Gemini Healthcare, LLC
Gemini Healthcare, LLC is a healthcare marketing company based in Westbrook, Connecticut. "
target: MCM Group
The MCM Group is a healthcare communications organization. We deliver comprehensive marketing, communications and consulting solutions for pharmaceutical and biotech companies. What's uncommon about us? Superior insight.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/27/2007 via PR Newswire

Thomson Pharma, acquired Prous Science

synopsis: The Thomson Corporation, a leading provider of information solutions to business and professional customers worldwide, today announced that it has acquired Prous Science, a global leader in the provision of life sciences information solutions. Prous Science will become part of Thomson Scientific.
buyer parent: The Thomson Corporation
buyer: Thomson Pharma (:$964.58)
Thomson Scientific & Healthcare provides integrated information solutions to researchers and librarians, physicians and pharmacists, and other professionals worldwide. "
target: Prous Science
Prous Science is a trusted source of information on which science depends to discover safer and more effective medicines. The company's products have evolved through the years from print journals to sophisticated electronic products incorporating the latest advances in IT.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2007 via Company Description

MergerMarket, acquired Infinata, Inc.

synopsis: In September 2007, Mergermarket acquired Infinata, an information solutions and marketing analytics provider to the global financial service, life science, and high technology industries.
buyer parent: Pearson plc
buyer: MergerMarket
MergerMarket, part of Pearson's Financial Times Group, is an unparalleled, independent M&A intelligence tool used by the world's foremost financial institutions to originate deals. It provides proprietary intelligence on potential deal flow, potential mandates and valuations. "
target: Infinata, Inc.
Infinata is an innovative provider of information solutions and marketing analytics to the global financial service, life science, and high-tech industries. Our information suites include: BioPharm Insight, High Net Worth Insight, and Corporate Tracker.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/25/2006 via PR Newswire

Thomson Pharma, acquired CMR International

synopsis: The Thomson Corporation today announced that it has completed the acquisition of Centre for Medicines Research International (CMR), the foremost provider of R&D performance metrics to the global pharmaceutical industry. CMR International, based in Epsom in the United Kingdom, is the world leader in global R&D performance measurement.
buyer parent: The Thomson Corporation
buyer: Thomson Pharma
Thomson Pharma is a dynamic, information offering for the pharmaceutical and biotechnology industries that is being developed by Thomson Scientific. "
target: CMR International
CMR International is the foremost provider of R&D performance metrics to the global pharmaceutical industry. Our ‘gold standard’ reputation in this field is based on an unrivalled record of assuring the confidentiality of the data we manage and analyse.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2019 via BNC Analysis

Inflexion Private Equity Partners LLP, will acquire Pharmaspectra

synopsis: Inflexion Private Equity, a UK mid-market private equity firm, will acquire Pharmaspectra, a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature.
buyer: Inflexion Private Equity Partners LLP
Inflexion is a UK mid-market private equity firm. They invest in high growth, entrepreneurial businesses and work with them to accelerate growth. Inflexion’s flexible approach allows it to back both majority and minority investments, typically investing £10m to £150m of equity in each deal. "
target: Pharmaspectra
Pharmaspectra is a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature. Their web-based solutions analyze data across the entire medical continuum.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/3/2013 via Company Press Release

JISC Collections, acquired SpringerProtocols

synopsis: Springer announced that JISC Collections has purchased the archive content of SpringerProtocols; the world’s largest database of life sciences protocols. SpringerProtocols contains more than 31,000 protocols, most of which come from the classic book series “Methods in Molecular Biology”.
buyer: JISC Collections
JISC Collections supports the procurement of digital content for education and research in the UK. They are uniquely placed to provide members with: expertise in negotiating and procurement, within the scholarly communications sector. "
target parent: EQT
target: SpringerProtocols
SpringerProtocols combines the world’s largest collection of life sciences and bio-medicine protocols with advanced search functionality. Used primarily in the life sciences, the protocols provide sets of instructions that allow scientists to recreate experiments in their own laboratories.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2013 via Yahoo, Inc.

Elsevier B.V., acquired Aureus Sciences

synopsis: Elsevier announced the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies. Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles. "
target: Aureus Sciences
Aureus Sciences provides scientific databases and software applications for researchers involved in the drug discovery and development process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/29/2010 via PR Newswire

Thomson Scientific & Healthcare, acquired GeneGo Inc.

synopsis: Thomson Reuters announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development. Effective immediately, GeneGo will become part of the Healthcare & Science business of Thomson Reuters.
buyer parent: Thomson Reuters
buyer: Thomson Scientific & Healthcare (:$964.58)
Thomson Scientific & Healthcare provides integrated information solutions to researchers and librarians, physicians and pharmacists, and other professionals worldwide. "
target: GeneGo Inc.
GeneGo is a leading provider of data mining & analysis solutions in systems biology. GeneGo's data mining tools and databases help to capture and define the underlying biology behind different types of high-throughput experimental data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/15/2016 via PR Newswire

The WIRB-Copernicus Group, will purchase Clinical Trial Applications from karmadata

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality of clinical research, will acquire from karmadata a suite of proprietary applications designed to facilitate the management of clinical trial data. karmadata is the market leader in clinical trial database and decision support applications.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
seller: karmadata
Karmadata is able to standardize and link the world's healthcare data ranging from leading open data sources to priva pharmacy and medical claims. Its propriety applications are designed to facilitate the management of clinical trial data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/3/2016 via PR Newswire

IMS Health Incorporated, acquired AlphaImpactRx, Inc

synopsis: Symphony Technology Group announced the closing of the sale of AlphaImpactRx, a leading provider of primary research and analytics-based insight for biopharmaceutical and consumer health companies to IMS Health, a global information and technology services company serving the healthcare industry.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target parent: Symphony Technology Group
target: AlphaImpactRx, Inc
AlphaImpactRx is the leading provider of primary research-based insights, analytics and solutions to pharmaceutical, consumer health and medical device companies. They provide market research to help its global healthcare clients make informed and business decisions to market their products.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/7/2013 via Wall Street Journal

Wilmington Group plc, acquired NHiS Ltd

synopsis: Wilmington Group plc, the provider of Information, Compliance, and Education to professional markets announced the acquisition of the entire issued and to be issued share capital of NHiS Limited. NHiS is a leading provider of business intelligence, data analysis, workflow tools and other services to pharmaceutical companies in the UK.
buyer: Wilmington Group plc (LSE:WIL:$162.62)
Wilmington Group plc is a dynamic and expanding company providing information and training to professional business markets. Their businesses enable professionals and their organizations to perform better by providing quality, relevant and reliable information, education and knowledge. "
target: NHiS Ltd
NHiS is the leading provider of market intelligence and insight to the pharmaceutical sector. NHiS’s products assist organizations in their understanding, engagement and optimization of their markets.
price ($mm)
$8.82
rev ($mm)
$3
EBITDA ($mm)
EV / rev
5.2x
EV / EBITDA
closed 8/30/2007 via Company Press Release

Entelos Inc., acquired Iconix Biosciences, Inc.

synopsis: Entelos, Inc., a leading life sciences company that leverages its proprietary in silico disease models, known as PhysioLab® platforms, to develop drugs and support pharmaceutical R&D, is pleased to announce that it has entered into an agreement to acquire Iconix Biosciences, Inc., a privately held predictive toxicology company
buyer: Entelos Inc.
Entelos partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease and dramatically reduce the time and cost needed to develop them. Using our patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. "
target: Iconix Biosciences, Inc.
Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix®)
price ($mm)
$7.73
rev ($mm)
$5
EBITDA ($mm)
EV / rev
6.7x
EV / EBITDA
closed 8/30/2007 via Company Press Release

Entelos Inc., acquired Iconix Biosciences, Inc.

synopsis: Entelos, Inc., a leading life sciences company that leverages its proprietary in silico disease models, known as PhysioLab® platforms, to develop drugs and support pharmaceutical R&D, is pleased to announce that it has entered into an agreement to acquire Iconix Biosciences, Inc., a privately held predictive toxicology company
buyer: Entelos Inc.
Entelos partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease and dramatically reduce the time and cost needed to develop them. Using our patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. "
target: Iconix Biosciences, Inc.
Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix®)
price ($mm)
$7.73
rev ($mm)
$5
EBITDA ($mm)
EV / rev
6.7x
EV / EBITDA
closed 5/26/2005 via PR Newswire

Entelos Inc., acquired Discovery Innovations, Inc.

synopsis: Entelos, Inc., the leader in biosimulation technologies for pharmaceutical research and development, announced today the acquisition of Discovery Innovations, a specialized provider of data integration products and services to the life sciences.
buyer: Entelos Inc.
Entelos partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease and dramatically reduce the time and cost needed to develop them. Using our patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. "
target: Discovery Innovations, Inc.
Discovery Innovations is a specialized provider of web-based products and information services to the life sciences. Recognizing the tidal wave of information being generated in the life sciences, Discovery Innovations has developed products and services that more efficiently access, deliver and sha
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/6/2019 via PR Newswire

Thermo Fisher Scientific, Inc., acquired HighChem, Ltd.

synopsis: Thermo Fisher Scientific, the world leader in serving science, announced that it has completed the acquisition of HighChem, Ltd., a leading developer of mass spectrometry software based in Bratislava, Slovakia. HighChem software solutions are used to analyze complex data and identify small molecules in pharmaceutical and metabolomics laboratories.
buyer: Thermo Fisher Scientific, Inc. (TMO:$24,630.00)
Thermo Fisher Scientific Inc. is the world leader in serving science, helping their customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. "
target: HighChem, Ltd.
HighChem, Ltd. is a leading developer of mass spectrometry software based in Bratislava, Slovakia. HighChem software solutions are used to analyze complex data and identify small molecules in pharmaceutical and metabolomics laboratories.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/14/2019 via PR Newswire

GraphPad Software, Inc., acquired SnapGene

synopsis: GraphPad Software, the leading provider of software developed exclusively for the scientific community, announced it has acquired SnapGene, a leading bioinformatics software solution that provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures.
buyer: GraphPad Software, Inc.
GraphPad is the leading provider of software developed exclusively for the scientific community. GraphPad Prism, their flagship product, is the preferred analysis and graphing solution for scientific research. Prism helps scientists discover and share the story in their data. "
target: SnapGene
SnapGene was founded by scientists and software designers to meet the everyday needs of molecular biologists. Their software provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2013 via BNC Analysis

Qiagen N.V., acquired CLC bio A/S

synopsis: Qiagen, a Netherlands holding company that ia a leading global provider of Sample & Assay Technologies, used to transform biological materials into valuable molecular information, acquired CLC bio, a global leader in bioinformatics software with a focus on next-generation sequencing (NGS).
buyer: Qiagen N.V. (QGEN:$1,269.61)
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies, used to transform biological materials into valuable molecular information. Qiagen has four customer classes: Molecular Diagnostics, Applied Testing, Pharma, & Academia. "
target: CLC bio A/S
CLC bio is the world's leading bioinformatics solution provider and the only one that provides both desktop and server software seamlessly integrated and optimized for best performance. The company is headquarted in Aarhus, Denmark.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/3/2012 via BusinessWire

CLC bio A/S, acquired Molegro

synopsis: CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
buyer: CLC bio A/S
CLC bio is the world's leading bioinformatics solution provider and the only one that provides both desktop and server software seamlessly integrated and optimized for best performance. The company is headquarted in Aarhus, Denmark. "
target parent: Østjysk Innovation A/S
target: Molegro
Founded in 2005, Molegro is a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/8/2011 via PR Newswire

Elsevier B.V., acquired Ariadne Genomics, Inc.

synopsis: Elsevier, a world-leading provider of scientific, technical, and medical information products and services, announced the acquisition of the business assets of Ariadne Genomics, a provider of pathway analysis tools and semantic technologies for life science researchers. Ariadne will be integrated with Elsevier's Corporate Markets division.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals and close to 20,000 book titles. "
target: Ariadne Genomics, Inc.
Ariadne Genomics, a leader in research data products and knowledge enrichment-based software solutions, helps pharmaceutical and life science researchers tap known scientific knowledge for applications in systems biology and translational medicine.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Company Press Release

Microsoft Corporation, will acquire Rosetta Biosoftware

synopsis: Microsoft Corp. announced that it has signed an agreement with Merck & Co. Inc. to acquire certain assets of Rosetta Biosoftware. The deal allows Microsoft to incorporate genetic, genomic, metabolomic and proteomics data management software into the Microsoft Amalga Life Sciences platform for enhanced translational research capabilities.
buyer: Microsoft Corporation (MSFT:$125,843.00)
Founded in 1975, Microsoft is the worldwide leader in software, services and solutions that help people and businesses realize their full potential. "
target parent: Merck & Co., Inc.
target: Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of enterprise bioinformatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Luminator gene expression data analysis systems, are designed to empower researchers to accelerate discovery.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/31/2005 via BusinessWire

Simulations Plus, Inc., acquired Sage Informatics LLC

synopsis: Simulations Plus, Inc., today announced that it has acquired the assets of Sage Informatics LLC of Santa Fe, New Mexico, a chemistry software company providing research tools to the pharmaceutical and biotechnology industries.
buyer: Simulations Plus, Inc. (SLP:$21.09)
Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) neural net and simulation software for the pharmaceutical and biotechnology industries today. Its software allows pharmaceutical scientists to predict certain key potential drug d "
target: Sage Informatics LLC
Sage Informatics is a chemistry software company providing research tools to the pharmaceutical & biotechnology industries. Their products include desktop applications, embeddable object components & native source code. They also offer technical software consulting & application development.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/24/2011 via BusinessWire

PerkinElmer, Inc., will acquire CambridgeSoft Corporation

synopsis: PerkinElmer, Inc. has announced that it has signed a definitive agreement to acquire CambridgeSoft Corporation, a leading supplier of discovery, collaboration, and knowledge enterprise solutions, desktop software, scientific databases and professional services to the pharmaceutical, biotechnology, and chemical industries.
buyer: PerkinElmer, Inc. (PKI:$2,209.40)
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. It designs, manufactures and delivers advanced technology solutions that address the world's most critical health and safety concerns. "
target parent: Health Evolution Partners LLc
target: CambridgeSoft Corporation
CambridgeSoft Corporation is a leading supplier of discovery, collaboration, and knowledge enterprise solutions, desktop software, scientific databases and professional services to the pharmaceutical, biotechnology, and chemical industries.
price ($mm)
$227
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/11/2019 via PR Newswire

InVitae, will acquire Jungla Inc.

synopsis: Invitae, a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare, will acquire Jungla, an artificial intelligence driven biotechnology company utilizing computational and cellular modeling to improve clinical genetic tests.
buyer: InVitae (NVTA:$195.90)
Invitae is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare. They aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. "
target: Jungla Inc.
Jungla Inc. is an artificial intelligence driven biotechnology company utilizing computational and cellular modeling to improve clinical genetic tests. Jungla's technologies combine advances in functional genomics, computational biophysics, cellular engineering, and computer science.
price ($mm)
$50
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/12/2014 via Company Press Release

Wiley, acquired SimBioSys Inc.

synopsis: John Wiley & Sons, Inc., a global provider of knowledge and knowledge-enabled solutions that improve outcomes in research, professional practice, and education, announced that it has acquired SimBioSys Inc., a provider of scientific software tools that facilitate the drug discovery process.
buyer: Wiley (NYSE:JW.A:$1,800.07)
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice, and education. "
target: SimBioSys Inc.
SimBioSys is a recognized leader in the field of rational drug discovery software. Providing a wide range of software solutions, the company is focused on the development of scientific tools to facilitate the drug discovery process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/6/2016 via PR Newswire

Twist Bioscience, acquired Genome Compiler Corporation

synopsis: Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, announced the acquisition of Genome Compiler Corporation, an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists.
buyer: Twist Bioscience
At Twist Bioscience, their expertise is accelerating science and innovation by leveraging the power of scale. They have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools. "
target: Genome Compiler Corporation
Genome Compiler Corporation is an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists. Their aim is to build a best-in-class CAD system and a synthetic DNA marketplace for the new and growing community of biological designers around the world.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/12/2018 via BusinessWire

Medidata Solutions Worldwide, will acquire SHYFT Analytics

synopsis: Medidata announced that it has entered into a definitive agreement to acquire SHYFT Analytics, bringing the leading platform for clinical development together with the leading platform for commercial and real-world data analytics.
buyer: Medidata Solutions Worldwide (MDSO:$660.00)
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. "
target: SHYFT Analytics
SHYFT Analytics is the leading cloud data analytics platform for life sciences with solutions designed exclusively for the pharmaceutical and biotech industry.
price ($mm)
$195
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/23/2017 via BusinessWire

Omicia, acquired Spiral Genetics

synopsis: Omicia, Inc., a leading provider of clinical genomic data analysis and reporting software, announced that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next generation sequencing (NGS) to Omicia’s industry-leading software platform.
buyer: Omicia
Clinicians and scientists utilize Omicia’s tools to quickly process and analyze genomic data and ultimately improve patient outcomes. Headquartered in Oakland, California, Omicia was founded by renowned scientists and industry veterans who are pioneers in bioinformatics, genomics and diagnostics. "
target: Spiral Genetics
Headquartered in Seattle, WA, Spiral Genetics is a bioinformatics company that develops high performance software for analyzing next-generation sequencing data. They specialize in large-scale DNA data analysis for medical, pharmaceutical and agricultural research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2007 via BusinessWire

Vector Capital, purchased Discovery Informatics business from Tripos, Inc.

synopsis: Tripos, Inc. completed the sale of the assets of its Discovery Informatics business to affiliates of Vector Capital. Vector Capital is a San Francisco-based private equity boutique specializing in buyouts, spinouts and recapitalizations of established technology businesses.
buyer: Vector Capital
Vector Capital is a private equity boutique specializing in spinouts, buyouts and recapitalizations of established technology businesses. Vector identifies and pursues these complex investments in both the public and private markets. "
seller: Tripos, Inc.
Tripos combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/5/2005 via BusinessWire

Tripos, Inc., acquired Optive Research Inc.

synopsis: Tripos, Inc., today announced that it has acquired privately held Optive Research, Inc., a recognized leader in developing innovative software for computer-assisted molecular discovery, for $4.75 million in cash and 599,521 shares of Tripos stock.
buyer parent: Vector Capital
buyer: Tripos, Inc.
Tripos combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. "
target: Optive Research Inc.
Optive Research is a science-driven software company developing products and solutions for more effective molecular discovery in the pharmaceutical, biotechnology, agrochemical, and related life science industries. Based on a 25-year history of providing solutions for faster, more effective, and mo
price ($mm)
$7.97
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/5/2019 via PR Newswire

Beckman Coulter, Inc, acquired Cytobank

synopsis: Beckman Coulter, a company that is advancing healthcare to enhance the diagnostic laboratory’s role in improving healthcare outcomes, announced its acquisition of Cytobank, a cloud-based analysis platform utilizing machine learning algorithms for collaborative biomedical research.
buyer parent: Danaher Corporation
buyer: Beckman Coulter, Inc (BEC:$0.00)
Beckman Coulter is committed to advancing healthcare by applying science, technology and the creativity of their teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Their diagnostic systems are used in complex biomedical testing and are found around the globe. "
target: Cytobank
Cytobank Inc. is a cloud-based analysis platform utilizing machine learning algorithms for collaborative biomedical research. Pharmaceutical, biotechnology, and academic researchers around the world use their SaaS solution to develop deep understandings of complex biology at the single cell level.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/1/2006 via BusinessWire

Media Cybernetics Inc., acquired AutoQuant

synopsis: Media Cybernetics Inc., the leading scientific image analysis software provider is pleased to announce their acquisition of the assets of AutoQuant of Troy, NY. AutoQuant specializes in image restoration, visualization, and analysis software products for life science microscopy.
buyer: Media Cybernetics Inc.
Founded in 1981, Media Cybernetics develops image informatics solutions to automate research, development, and quality control processes in life science and industry. "
target: AutoQuant
Bringing the best in deconvolution, visualization and analysis software to life science microscopists since 1994, AutoQuant has earned its place as the leader for quantitative microscopy solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2017 via BNC Analysis

BGene Genetics SAS, acquired CAD4Bio SAS

synopsis: BGene Genetics has acquired CAD4Bio, a company specialised in the development of software dedicated to molecular biology. CAD4Bio software supports biologists throughout the design process of genomic constructions, controls their high-throughput construction and capitalises on experience through a machine learning module.
buyer: BGene Genetics SAS
BGene Genetics is a company specialised in metabolic and genetic engineering of microbial production strains that aims to develop more environmentally production ways. BGene develops bacteria able to produce molecules in a sustainable way from non food and renewable raw materials. "
target: CAD4Bio SAS
CAD4Bio has developed a software of computer-aided design for molecular biology. The software supports the biologist throughout the design process of genomic constructions, controls their high-throughput construction and capitalised on experience through a machine learning module.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/5/2016 via BNC Analysis

bioMérieux S.A., acquired Applied Maths

synopsis: bioMérieux, a world leader in the field of in vitro diagnostics, announced the acquisition of Applied Maths, a company that develops state-of-the-art software solutions for the biosciences, in particular for databasing, analysis and interpretation of complex biological data.
buyer: bioMérieux S.A. (ENXTPA:BIM:$1,996.55)
A world leader in the field of in vitro diagnostics for 50 years, bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. "
target: Applied Maths
Applied Maths develops cutting-edge software for the biosciences. The company has gained worldwide recognition with its software GelCompar for the analysis of 1D gel patterns, and later even more with BioNumerics, a software suite for integrated databasing and analysis of biological data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/28/2013 via Company Press Release

Illumina, Inc., acquired NextBio, Inc.

synopsis: Illumina, Inc. has acquired Santa Clara-based NextBio, a leader in clinical and genomic informatics. NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data.
buyer: Illumina, Inc. (ILMN:$3,243.00)
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. They provide innovative sequencing and array-based solutions. "
target: NextBio, Inc.
NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Iconix Biosciences, Inc.


read more

Iconix Biosciences, Inc.

Dymaxium, Inc.

Vidal Group

MedicalDirector

Avalere Health LLC

Decision Resources Group

Edital

Medical Intelligence Solutions

MCM Group

Prous Science

Infinata, Inc.

CMR International

Pharmaspectra

SpringerProtocols

Aureus Sciences

GeneGo Inc.

CenterWatch, Inc.

karmadata

AlphaImpactRx, Inc

NHiS Ltd

read more

Iconix Biosciences, Inc.

read more

Iconix Biosciences, Inc.

Discovery Innovations, Inc.

read more

HighChem, Ltd.

SnapGene

CLC bio A/S

Molegro

Ariadne Genomics, Inc.

Rosetta Biosoftware

Sage Informatics LLC

CambridgeSoft Corporation

Jungla Inc.

SimBioSys Inc.

Genome Compiler Corporation

SHYFT Analytics

Spiral Genetics

Tripos, Inc.

Optive Research Inc.

Cytobank

AutoQuant

CAD4Bio SAS

Applied Maths

NextBio, Inc.

Geography
Matching Companies
Ticker: NYSE:IQV
 
 
 
 
 
 
 
 
IQVIA
IQVIA
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services.
year
2018
rev ($mm)
$10,412.00
EBITDA ($mm)
$1,950.00
EBIT ($mm)
$809.00
Net Income ($mm)
$259.00
Employees
58000
  • drill down
  • watch
Ticker: ENXTPA:CGM
 
 
 
 
 
 
 
 
Cegedim
Cegedim
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases.
year
2018
rev ($mm)
$512.82
EBITDA ($mm)
$50.20
EBIT ($mm)
$33.91
Net Income ($mm)
$6.33
Employees
4468
  • drill down
  • watch
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3.com
M3.com
M3.com is Japan's largest portal site dedicated to healthcare professionals. M3.com provides the latest medical news, overseas journal article summaries, and medical resources. The portal offers information on clinical trials and other services in the healthcare and pharmaceutical industries.
year
2019
rev ($mm)
$1,015.17
EBITDA ($mm)
$288.13
EBIT ($mm)
$275.64
Net Income ($mm)
$175.78
Employees
5165
  • drill down
  • watch
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3, Inc.
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet.
year
2019
rev ($mm)
$1,110.45
EBITDA ($mm)
$306.07
EBIT ($mm)
$279.73
Net Income ($mm)
$191.17
Employees
6024
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
Clarivate Analytics
Clarivate Analytics
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management.
year
2019
rev ($mm)
$964.58
EBITDA ($mm)
$154.61
EBIT ($mm)
($47.97)
Net Income ($mm)
Employees
4515
  • drill down
  • watch